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n recent years, it has become evident that the majority of the human genome has been transcribed, but only 2% to 3% of the transcripts encode for proteins. Among the noncoding RNAs, small noncoding RNAs, such as microRNAs, can posttranscriptionally control gene expression by binding to targeted mRNA, whereas long noncoding RNAs (lncRNAs) can interfere with gene expression and post-transcriptional signaling at various levels.
1 lncRNAs can directly interact with DNA to recruit epigenetic modulators, act as a decoy for transcription factors, control splicing, or interact with proteins to control protein complex formation or functions, and some lncRNAs may act as sponges for microRNAs.
1,2 Some recent studies suggest that lncRNAs play a crucial role in vascular biology and cardiovascular disease. 2, 3 For example, inhibition of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1, also known as NEAT2 [nuclear-enriched abundant transcript 2]), which was initially discovered as a tumor-associated lncRNA that controlled proliferation and metastasis, 4, 5 was shown to reduce endothelial cell 6 and smooth muscle cell 7 proliferation in vitro. In vivo silencing or genetic deletion of MALAT1 reduced neovascularization 6 and improved diabetic retinopathy. 8 Other studies identified the lncRNA MEG3 (maternally expressed 3) as a proangiogenic lncRNA, 9 whereas SENCR (smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA) regulates smooth muscle functions. 10 The mechanisms underlying the reported functional effects of lncRNAs in the vasculature and their role in atherosclerosis are largely unknown. Atherosclerosis is the major cause of vessel occlusion leading to myocardial infarction or stroke. The development of atherosclerotic lesions is a complex process initially facilitated by activation of the endothelium, which allows the recruitment of inflammatory cells and proliferation of smooth muscle cells. 11, 12 In particular, a diverse set of hematopoietic cells involved in innate or adaptive immunity, such as T cells, macrophages, dendritic cells, and neutrophils, contribute to atherosclerotic lesion development but also to plaque destabilization by releasing multiple cytokines and chemokines. 13 On the basis of the finding that MALAT1 is highly expressed in vascular and inflammatory cells and regulates endothelial and smooth muscle cell functions in vitro, we determined the role of this lncRNA in atherosclerotic lesion development in vivo.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Mice
All animal experiments were conducted according to the principles of laboratory animal care and according to German national laws. The studies were approved by the local ethics committee (Regierungspräsidium Darmstadt, Hessen). Malat1 -/-mice were a gift from M. Zörnig. Apoe -/-mice were obtained form JAX (Stock No. 0664). Malat1 -/-mice and genotyping were described previously.
14 Female mice were used for the atherosclerosis experiments. Malat1 −/− and Malat1 +/+ mice were crossed with apolipoprotein E-deficient (Apoe −/− ) mice on a C57Bl6 background. Mice were fed a high-fat diet (D12492, 34% fat [265 mg/kg cholesterol], 24% sugar; ssniff Spezialdiaeten, Soest, Germany) for 12 weeks. After the mice were killed, aortas and aortic roots and arches were excised and processed for histology. Aortic roots were embedded in paraffin or OCT.
Bone Marrow Transplantation
Apoe −/− Malat1 +/+ mice were exposed to 9 Gy of total body irradiation using a roentgen source. The next day, bone marrow cells (BMCs) were obtained from Apoe −/− Malat1 −/− or Apoe −/− Malat1 +/+ mice by flushing the femurs and tibias of the donor mice with PBS. Cell suspensions were prepared by passing the cells through a 50-µm nylon mesh. Irradiated recipients received 1×10 7 BMCs by tail vein injection. Two weeks after transplantation, repopulation was assessed by measuring MALAT1 expression in peripheral blood leukocytes, and a high-fat diet was started for 16 weeks (D12492, 34% fat; ssniff Spezialdiaeten). After the mice were killed, transplantation efficacy was again controlled by quantitative polymerase chain reaction of BMCs. Aortas, aortic roots, and aortic arches were excised. BMCs were isolated as described previously in PBS with 0.5% BSA. After red blood cell lysis, cells were used for flow cytometry or RNA isolation.
Clinical Perspective
What Is New?
• Our study demonstrates for the first time the importance of a long noncoding RNA in atherosclerotic lesion development in mice and humans.
• The long noncoding RNA MALAT1 protects from atherosclerosis by regulating inflammation.
• MALAT1 deficiency in leukocytes leads to increased myeloid cell adhesion to the vessel wall and increased cytokine production.
• The anti-inflammatory properties of MALAT1 are mediated at least in part via interfering with miRNAs, in particular miR-503.
What Are the Clinical Implications?
• Our findings derived from murine atherosclerosis models translate into clinical significance: reduced MALAT1 levels were detected in human atherosclerotic lesions of symptomatic patients.
• Reduced MALAT1 levels in human atherosclerotic lesions were associated with a poor prognosis.
• Atherosclerosis might elicit dynamic changes in expression patterns of noncoding RNAs that could be exploited in the future, finally paving the way for therapeutic agents directed against RNAs.
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Histology
For en face staining of the plaque area in mice, the aorta (including aortic arch and thoracic and abdominal regions) was opened longitudinally and fixed with 4% paraformaldehyde overnight at 4°C. After they were washed and incubated with isopropanol, aortas were stained with Oil Red O (Sigma-Aldrich [now MilliporeSigma], St Louis, MO) to detect lipids and determine lesion area. En face images of the aorta were taken with a digital camera and analyzed with ImageJ. Atherosclerotic lesions of the aorta were expressed as a percentage of the total surface area. Aortic roots were sliced into 4-µm sections. The paraffinembedded sections were deparaffinized and rehydrated, and Masson trichrome staining was performed. Sections were stained with antibodies against smooth muscle actin-Cy3 (MilliporeSigma, clone 1A4) and CD45 (Abcam, clone I3/2.3). OCT-embedded sections were stained with Oil Red O as described previously, as well as with antibodies against F4/80 (Bio-Rad, clone 3:A1) and Gr1 (eBioscience, clone RB6-8C5). Alexa Fluor 555 goat anti-rat IgG was used as secondary antibody. Nuclei were counterstained with DAPI, and sections were mounted with Fluoromount aqueous mounting medium (DAKO). Slides were scanned with an LSM 780 confocal microscope (Zeiss, Germany) at ×40 magnification. Oil Red O stains were scanned with a digital camera. Images were analyzed with ImageJ.
Flow Cytometry
Single-cell suspensions of blood and bone marrow were obtained. Afterward, cells were stained with antibodies against Sca1 and c-kit and with anti-mouse lineage antibody cocktail (all from BD). To identify macrophages, neutrophils, and dendritic cells, antibodies against CD11b, CD 11c, B220, Ly6C, Ly6G (all from BD), and F4/80 (AbD Serotec) were used. Monocytes were identified as CD11b + Ly6G− Ly6C 
Intravital Microscopy
Leukocyte-endothelial interactions along the carotid artery were analyzed by intravital epifluorescence microscopy. Mice were placed in a supine position, and the right jugular vein was cannulated with a catheter for antibody injection. Intravital microscopy was performed after injection of antibodies to Ly6G (1 µg; clone 1A8, eBioscience), Ly6C (1 µg; HK1.4, BioLegend), and CD11b (1 µg; M1/70, eBioscience) with an Olympus BX51 microscope equipped with a Hamamatsu 9100-02 EMCCD (electron multiplying charge-coupled device) camera and a 10× saline immersion objective. Thirty-second movies were acquired and analyzed offline. Rolling flux was assessed as a cell moving across a line perpendicular to the carotid artery. Cells were considered adherent if they did not move during the 30 seconds.
Isolation of CD45 + and Neutrophils From Murine Bone Marrow
CD45
+ leukocytes were isolated with microbeads against CD45 (Miltenyi Biotech, Bergisch Gladbach, Germany). Briefly, after the bones were flushed, single-cell suspensions were centrifuged and resuspended in cold PBS that contained 0.5% BSA and 2 mmol/L EDTA. Cells were incubated with anti-CD45 microbeads for 15 minutes. After washing, cells were separated using an MACS (magnetic-activated cell sorting) separator with MACS LS columns. For neutrophil isolation, a neutrophil isolation kit was used (Miltenyi Biotech). Cells were incubated with neutrophil biotin antibody cocktail, followed by incubation with anti-biotin microbeads and MACS separation with MACS LS columns. Neutrophils were incubated in RPMI medium for 1 hour, followed by stimulation with lipopolysaccharide (LPS) 100 µg/mL (MilliporeSigma) for 4 hours. Supernatants were obtained by centrifugation, and cytokine profiles were measured with a proteome profiler array (mouse cytokine array panel A; R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Lipid Analysis
Using cardiac puncture, blood was drawn from Apoe −/−
Malat1
−/− mice and collected in tubes without anticoagulant. Blood was kept at room temperature for an hour, followed by a spin (1500g) at 4°C for 15 minutes. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured by an enzymatic colorimetric assay (CHOL2, TRIGL, and HDLC3, all from Roche Diagnostics, Mannheim, Germany). Low-density lipoprotein levels were calculated with the Friedewald equation.
Adhesion Assay
Cell-cell adhesion was performed as described previously. 15 Freshly isolated lung endothelial cells or an immortalized mouse endothelial cell line (H5V, gift from E. Dejana) was used. Microvascular lung endothelial cells were isolated from wild-type mice. Endothelial cell monolayers were grown to confluence and were stimulated with tumor necrosis factor-α (10 ng/mL) for 24 hours as indicated. BMCs were isolated from murine femurs by density centrifugation with Ficoll and were stimulated with PMA (50 ng/µL) where indicated. For microRNA (miR-503) inhibition, BMCs were transfected with control locked nucleic acid or miR-503 locked nucleic acid (100 nmol/L) 24 hours before the experiments. Mononuclear cells were stained with BCECF-AM (Molecular Probes, Eugene, OR), and cells were resuspended in RPMI 1640 with 0.05% BSA. A total of 100 000 cells/well (in 100 μL of RPMI 1640 with 0.05% albumin) were added to the microvascular monolayers, and after incubation for 20 minutes at 37°C, plates were washed with warm RPMI 1640 to remove nonadherent cells. Adherent cells were quantified in triplicate with a fluorescence plate reader (Synergy HT, BioTek, Bad Friedrichshall, Germany).
RNA Isolation and Quantitative RealTime Polymerase Chain Reaction
For RNA isolation of cell suspensions, cells were lysed with QIAzol (Qiagen, Hilden, Germany). Total RNA from mouse tissue and from isolated cells was isolated with miRNeasy kits (Qiagen) according to the manufacturer's protocol. One hundred to 1000 ng of total RNA was reverse transcribed with MulV reverse transcriptase (Life Technologies) and random hexamer primers (Thermo Scientific, Waltham, MA) in a 20-μL reaction. cDNA was used as the template for quantitative real-time reverse transcriptase-polymerase chain reaction with Fast SYBR Green (Applied Biosystems, Forster City, CA) and an Applied Biosystems StepOnePlus machine. Mouse ribosomal P0 (RPLP0) mRNA was used for normalization.
For determination of miRNA expression levels, TaqMan microRNA assays (Applied Biosystems) were used. Quantitative polymerase chain reactions were performed on a StepOnePlus device (Applied Biosystems). miRNA expression was normalized to U6 as endogenous control. Analysis of relative gene expression levels was performed using the formula 2−ΔCT, with ΔCT=CT (target gene)-CT (control), where CT indicates cycle threshold.
RNA Sequencing
For RNA sequencing, RNA was isolated from CD45 + BMCs using the miRNeasy Micro Kit (Qiagen) combined with oncolumn DNase digestion (RNase-Free DNase Set, Qiagen) to remove contaminating genomic DNA. RNA and library preparation integrity were verified with a BioAnalyzer 2100 (Agilent) or LabChip GX Touch 24 (PerkinElmer). One microgram of total RNA was used as input for the SMARTer Stranded Total RNA Sample Prep Kit -HI Mammalian (Clontech). Sequencing was performed on a NextSeq500 instrument (Illumina) using v2 chemistry, which resulted in a minimum of 50 million reads per library with 2×75 bp paired-end setup. The resulting raw reads were assessed for quality, adapter content, and duplication rates with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Reaper version 13-100 was used to trim reads after a quality drop below a mean of Q20 in a window of 10 nucleotides. 16 Only reads between 30 and 75 nucleotides were cleared for further analyses. Trimmed and filtered reads were aligned versus the Ensembl genome version mm10 (GRCm38) using STAR 2.4.0a with the parameter "-outFilterMismatchNoverLmax 0.1" to increase the maximum ratio of mismatches to mapped length to 10%. 17 The number of reads aligning to genes was counted with the featureCounts 1.4.5-p1 tool from the Subread package. 18 Only reads that mapped at least partially inside exons were admitted and aggregated per gene. Reads that overlapped multiple genes or aligned to multiple regions were excluded. Differentially expressed genes were identified with DESeq2 version 1.62. 
NanoString Measurement
NanoString analysis was performed with 100 ng of total RNA using the nCounter miRNA expression assay (NanoString) according to the standard protocol. Hybridization of RNA with the probes was performed overnight for 16 hours after preparation on nCounter Prep station (NanoString) with the high-sensitivity protocol. Cartridge was stored at 4°C until analysis on the digital analyzer (NanoString). Normalization and data analysis were performed on nSolver Software version 2.6 (NanoString).
Human Samples
Human tissues were part of the Biobank of Karolinska Endarterectomies (BiKE) at the Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden. Atherosclerotic plaques and clinical data were obtained from patients undergoing surgery for stable (asymptomatic) or unstable (symptomatic) carotid stenosis (>50% according to the NASCET [North American Symptomatic Carotid Endarterectomy Trial] method) at the Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden. Symptoms were defined as transitory ischemic attack, minor stroke, or retinal stroke (amaurosis fugax). Control normal arteries (nondiseased, macroscopically atherosclerosis-free arteries [iliac and 1 aorta]) were obtained from organ donors without any current or past cardiovascular disease. All samples were collected with informed consent from patients, organ donors, or their guardians. The study was approved by the ethics committee of northern Stockholm. The BiKE study cohort demographics and details of sample collection, processing, and full microarray analyses have been described previously. 20 Briefly, gene expression profiles were analyzed by Affymetrix HG-U133 plus 2.0 GeneChip microarrays in 127 patient plaque tissues and 10 normal arteries. Robust multiarray average normalization and correction for batch effect were performed, and processed gene expression data were returned in log2 scale. The microarray dataset is available from Gene Expression Omnibus (GSE21545). The BiKE database was merged with the Swedish Hospital Discharge Register and Swedish Cause of Death Register for follow-up of major adverse cardiovascular, cerebrovascular, and vascular events, as described previously. 21 Survival analysis was conducted with a Cox regression model with censored event-free survival as the response variable and log2-transformed MALAT1 levels as the explanatory variable. The covariates of age and sex were tested and had no effect on results. Bonferroni correction was applied to P values in all analyses, and P<0.05 after correction for multiple comparisons was considered to indicate statistical significance.
In Situ Hybridization
For in situ hybridization, we used an Exiqon miRCURY LNA DIG-labeled probe (5′-3′ sequence: /5DigN/AGATGGACA TTGCCTCTTCAT/3Dig_N/) with the accompanying kit and protocol (Exiqon, Vedbaek, Denmark). Tissue sections were derived from the BiKE cohort. In brief, tissue sections were deparaffinized (formalin-fixed paraffin-embedded) and rehydrated. Nucleases were inactivated with proteinase K followed by 2-hour hybridization at 54°C. Slides were washed in saline-sodium citrate buffers with subsequent DIG detection methods. In total, 6 plaques from carotid arteries and 4 nondiseased iliac arteries were analyzed.
Statistical Analysis
Data were analyzed with GraphPad Prism 7 using unpaired Student t test or nonparametric Mann-Whitney test when appropriate. Data were normalized to the control group to reduce batch effects in some experiments. Results are expressed as mean±SEM. P<0.05 was considered significant.
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RESULTS
MALAT1 Deficiency Alters Atherosclerotic Plaque Phenotype in Mice
To determine the role of MALAT1 in atherosclerosis, Malat1 −/− mice were crossed with Apoe −/− mice (for genotyping of Malat1 −/− mice, see Figure 1A ) and subsequently fed a high-fat diet for 12 weeks. Apoe 
MALAT1 Deficiency Regulates Hematopoietic Cells in Bone Marrow
Enhanced activity of BMCs is an important feature in progression of atherosclerotic disease. 
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than Apoe −/− Malat1 +/+ leukocytes ( Figure 4A ). A total of 340 of 46 073 genes were significantly regulated (P<0.05). Of these genes, the majority were downregulated (194 downregulated versus 146 upregulated genes; Figure 4C ). Highly regulated lncRNA and protein coding genes can be found in Tables I and II in Because many of those genes are regulators of neutrophil functions, neutrophil activation, as measured by cytokine production in the supernatants of LPS-activated neutrophils, was assessed. Here, higher amounts of cytokines could be detected in supernatants of Apoe −/−
Malat1
−/− than in Apoe −/− Malat1 +/+ cells ( Figure 4D ). In particular, the LPS-induced release of tumor necrosis factor-α and CXCL10 was significantly elevated in Malat1-deficient neutrophils ( Figure 4D) .
Interestingly, gene expression analysis revealed that more genes are repressed in Apoe −/− Malat1 −/− bone marrow leukocytes than in controls. Because MALAT1 Figure 4E) . Surprisingly, all of them were upregulated (Table III in the online-only Data Supplement). Of the upregulated microRNAs, 5 were predicted to be MALAT1 targets according to bioinformatics analysis with miRcode, namely, miR-503, miR-124, miR-384, miR-29, and miR-21 (Table III in the online-only Data Supplement). Because miR-21, miR-29, miR-124, and miR-503 are highly expressed and known for their vascular effects, we selected these miRNAs for further analysis. Of the 4 selected miRNAs, miR-503 was most profoundly and significantly regulated in the validation study ( Figure 4F ). To determine the mechanism underlying the regulation of miR-503, we ascertained the expression of the host gene and the processed primary miRNA (pri-miR-503), as well as the precursor and mature miR-322, which is expressed by the same host gene, and miR-503-3p and miR-503-5p. Interestingly, the host gene, primiR-503, miR-322, and miR-503-3p were not upregulated ( Figure 5A ), which suggests that MALAT1 acts as a sponge for miR-503-5p or interferes with later steps in selective processing of miR-503-5p. Furthermore, analysis of AGO2 PAR-CLIP data derived from murine macrophages 23 revealed a conserved microRNA binding site for miR-503 ( Figure IV in the online-only Data Supplement). To determine whether this regulation is also relevant in an atherosclerosis model in vivo, expression of miR-503 was measured in aortic roots of atherosclerotic mice. Indeed, miR-503 was significantly upregulated in aortic roots of Apoe −/− Malat1 −/− mice ( Figure 5B ). To investigate whether increased miR-503 levels affect the expression of its target genes in vivo, we measured the expression of the known miR-503 targets FGF2, Rictor, and Bcl2 24, 25 in splenic monocytes derived from Apoe −/− Malat1 +/+ and Apoe −/− Malat1 −/− mice. We confirmed that MALAT1 negatively correlates with miR-503 levels, which supports the hypothesis that MALAT1 can act as a sponge for miR-503. Indeed, we observed an inverse correlation between miR-503 and its target genes, particularly FGF2, which demonstrates the effect of MALAT1 on miR-503 target genes ( Figure V in the online-only Data Supplement). To determine whether the increased bioavailability of miR-503 contributes to the phenotype of Malat1
−/− BMC, we blocked miR-503 expression 
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by anti-miRs. Indeed, anti-miR-503 significantly rescued the enhanced adhesion of unstimulated or PMAstimulated Apoe −/− Malat1 −/− BMCs to tumor necrosis factor-α-activated endothelial cells and partially rescued the phenotype ( Figure 5C and 5D ).
MALAT1 Expression Is Downregulated in Advanced Human Atherosclerotic Plaques
To determine the relevance of the results of our mouse studies, we measured the expression of MALAT1 in ca- rotid plaques from atherosclerosis patients belonging to the BiKE cohort. 20 No significant associations with baseline patient clinical characteristics in this cohort (such as sex, age, various medications used, previous cardiovascular disease, serum cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, or plasma hemoglobin) could be found for MALAT1.
Next, analysis of the expression of MALAT1 examined in microarray datasets revealed that it was significantly downregulated in human plaques versus normal arteries ( Figure 6A ). The same trend was observed for MALAT1 by comparing plaques from symptomatic versus asymptomatic patients ( Figure 6B ). In validation of the microarray data, in situ hybridization confirmed that MALAT1 is enriched in normal arteries, whereas only weak signals could be detected in atherosclerotic plaques ( Figure 6C and 6D) . Overall, downregulation of MALAT1 in plaques appears to be associated with symptoms that characterize patient instability. 20 Next, we determined whether MALAT1 expression correlates with future adverse cardiovascular events.
We found that above-median MALAT1 expression levels in plaques were associated with fewer major adverse cardiovascular, cerebrovascular, and vascular events and better survival of patients during the follow-up period after surgery (hazard ratio, 2.386; 95% confidence interval, 1.3-5.2; P=0.0071; Figure 6E ). This finding again indicates that increased expression of MALAT1 in plaques may be beneficial and related to plaque stability with a favorable prognosis.
DISCUSSION
The data of the present study demonstrate that MALAT1 is a critical regulator of atherosclerosis in mice in vivo and is associated with human atherosclerotic lesion formation. Genetic deletion of MALAT1 enhanced atherosclerotic lesion formation, and a low expression of MALAT1 in human plaques was associated with advanced plaque stages and poor prognosis. Although we observed elevated atherosclerotic lesion formation in Malat1-deficient mice, the phenotype was not severe. This might be attributable to the compensation 
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of MALAT1 function by the upregulation of the family member NEAT1. In addition, we used a less aggressive diet (265 mg/kg cholesterol; 24% sugar) compared with the Western diet used in some other studies (1500 mg/kg cholesterol; 34% sugar), which might have contributed to a modest atherosclerotic lesion formation in the Apoe −/− background. Interestingly, the effects of MALAT1 deficiency on atherosclerotic lesion formation were further aggravated when Malat1-deficient bone marrow was transplanted, which suggests that MALAT1 primarily influences inflammatory responses regulating atherosclerosis. MALAT1 deficiency was previously shown to reduce endothelial cell proliferation, 6 and this might also have contributed to augmented atherosclerosis, particularly in the low-flow regions of the vascular tree, where endothelial cell proliferation is an important protective repair mechanism. 26 On the other hand, one may speculate that the inhibition of endothelial cell proliferation induced by MALAT1 deficiency could have reduced plaque angiogenesis, which would be antiatherosclerotic and as such could have counterbalanced the harmful effects on the luminal endothelial monolayer. In addition, proliferation of smooth muscle cells was reported to be regulated by MALAT1 in vitro. 7 The role of smooth muscle cells in atherosclerosis is complex, because proliferation of smooth muscle cells contributes to plaque growth, but smooth muscle cells also stabilize plaques. 12 In Malat1 −/− mice, no change in smooth muscle actin-positive cells was observed in plaques, demonstrating that the overall number of smooth muscle cells at this stage of atherosclerotic lesion development was not affected. Overall, MALAT1 effects in vascular cells appear not to be the most important mechanisms, because transplantation of Malat1 −/− cells fully recapitulated the phenotype observed in general knockout mice. However, because of the complex role of MALAT1 in endothelial or smooth muscle cell biology, one cannot rule out that MALAT1 regulates the function of these cells, but that the opposing biological consequences neutralize each other during atherosclerosis development. Cell-type-specific knockout mice, which are not available to us, would be necessary to decipher the specific functions of MALAT1 in the diverse cell types.
Our data clearly demonstrate that MALAT1 regulates hematopoietic cells and their functions. Thus, increased levels of hematopoietic progenitor cells and their progeny were observed after bone marrow transplantation of Apoe −/− Malat1 −/− mice compared with Apoe −/− Malat1 +/+ mice. Moreover, adhesion of BMCs to activated endothelium was augmented in vitro and in vivo in Apoe −/− Malat1 −/− mice, which argues for increased recruitment of proinflammmatory leukocytes into atherosclerotic lesions. Finally, LPS-induced release of cytokines by neutrophils was enhanced in Malat1-deficient cells. The increased release of cytokines observed in our study is consistent with the demonstration that MALAT1 deletion augments LPS-induced activation of macrophages. 27 Moreover, silencing of the MALAT1-derived mascRNA (MALAT1-associated small cytoplasmic RNA) fragment induced proinflammatory cytokines in THP-1 cells. 28 Together, it is conceivable that MALAT1 has several distinct effects on different inflammatory cells, which all can contribute to plaque inflammation.
With respect to the mechanism, our data demonstrate that the anti-inflammatory function of MALAT1 depends at least in part on binding of miRNAs, particularly miR-503. So far, the mechanisms underlying MALAT1 functions have predominantly been determined in tumor cells or cell lines. MALAT1 has been shown to epigenetically control gene expression by, for example, interacting with polycomb-2, which allows the relocation and transcriptional activation of growth-control genes, 29 and to regulate splicing by interfering with SR splicing factor proteins. 30 In addition, some studies report that MALAT1 binds to miRNAs and competitively interferes with miRNA functions. Thus, MALAT1 was shown to control miR-506, 31 miR-1, 32 miR-101b, 33 miR-200, 34 miR-145, 35 and miR-206 36 in different cell types. However, most studies focused on functional associations and did not biochemically confirm the mechanism, for example, by documenting AGO associations. In general, the concept that mRNAs or lncRNAs can act as microRNA sponges and functionally interfere with miRNA-mediated target gene repression has been challenged. 37 In the case of lncRNAs, the stoichiometry in particular is not in favor of such a mechanism, because in general, lncRNAs are expressed at much lower levels than miRNAs or their target genes. However, MALAT1 is among the most highly expressed transcripts of all coding and noncoding RNAs, and therefore, it may well be considered to act via this type of mechanism. In line with a putative sponge function of MALAT1, we showed that several miRNAs, among them miR-503, were significantly upregulated in Malat1-deficient cells and, more importantly, in aortic roots of atherosclerotic Apoe −/− Malat1 −/− mice. Moreover, the present study documents the association of MALAT1 with AGO at miR-503 binding in AGO PAR-CLIP data in murine macrophages. We also excluded an effect of MALAT1 on the transcription of the miR-503 host gene. Interestingly, the primary miR-503 was also not regulated, which suggests that MALAT1 could indeed act as a sponge or interfere with later stages of miR-503 processing. Although it is difficult to define the specific mechanism by which MALAT1 affects miR-503 levels, our finding showing that miR-503 is profoundly upregulated in Malat1-deficient mice and that inhibition of miR-503 rescues the enhanced adhesion of Malat1 −/− BMCs provides strong evidence for the biological relevance of this MALAT1 target.
MiR-503 is an intragenic microRNA, belonging to the miR-16 family. This family is ubiquitously expressed and has various functions, including effects on several aspects of cardiovascular biology. 38 MiR-503 itself impairs postischemic reparative angiogenesis in the setting of diabetes mellitus. 39 In monocytes, miR-503 is associated with macrophage differentiation and induces cell cycle arrest by affecting cell cycle regulatory genes. 40 These findings are consistent with our data showing more macrophages in Malat1 −/− mice. However, we also observed higher levels of stem/progenitor cells in vivo and upregulation of BMC adhesion, the latter effect being clearly reversed by miR-503 inhibition. These functions of miR-503 have not been reported before, and a more detailed analysis of the biological activities and targets of miR-503 in the hematopoietic system is warranted.
In summary, the present study demonstrates that MALAT1 is a critical regulator of atherosclerosis by regulating inflammatory cell number and functions. Part of the effects are attributed to interference with miR-503 function; however, the present study does not exclude that MALAT1 exhibits additional functions. MALAT1 could bind to other microRNAs and might also affect gene expression by epigenetic mechanisms or by interfering with proinflammatory transcription factors.
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